According to a research report Efficacy Testing Market is projected to reach USD 423 million by 2027 from USD 315 million in 2022, at a CAGR of 6.1% during the forecast period. Key drivers contributing to the market growth are the increasing use of surface disinfectants and preservatives in the pharma, biopharma, and cosmetics industries for contamination control and product stability; growing preference for outsourcing efficacy testing; and the rising adoption of the Quality by Design approach. The high growth potential in emerging markets will provide growth opportunities for players operating in the efficacy testing market. However, the adverse effects of chemical disinfectants is expected to hinder the growth of the market.

Download PDF Brochure:

Browse in-depth TOC on "Efficacy Testing Market”

143 – Tables

36 – Figures

181 – Pages

Key Market Players:

Prominent players in the optical imaging market include Carl Zeiss Meditec (Germany), Abbott (US), Topcon Corporation (Japan), Canon (Japan), PerkinElmer (US), Koninklijke Philips (Netherlands), Heidelberg Engineering (US), Leica Microsystems (Germany), Headwall Photonics (US), Visionix (US), Optical Imaging (Israel), Optos (Scotland), Wasatch Photonics (US), ArcScan (US), DermaLumics (Spain), Cylite (Australia), MOPTIM (Guangdong), Michelson Diagnostics (England), Thorlabs (US), Hamamatsu Photonics (Japan), iTheraMedical (Germany), Kibero (Germany), Seno Medical (US), Aspectus Imaging (Germany), and Agfa-Gevaert (Belgium).

Eurofins Scientific (Luxembourg) is a leading service provider in the efficacy testing market. The company has a strong geographical presence in Europe, North America, and the Asia Pacific. Eurofins Scientific provides testing and support services in different sectors, including the pharmaceutical, food, environment, agroscience, and genomics sectors across the world. The company operates through four business segments, namely, Sample-based Business, Study-based Business, FTE-based Business, and Product-based Business. Eurofins BPT NZ provides a wide range of GMP testing services for the pharmaceutical industry, including full microbiological testing, raw materials analysis, and stability storage trial. The company offers antimicrobial and disinfectant efficacy testing services through Eurofins’ BioPharma Product Testing laboratories located in Australia, Belgium, Canada, Denmark, France, Germany, India, Ireland, Italy, Japan, the Netherlands, New Zealand, Spain, Sweden, Switzerland, the UK, and the US.

Charles River Laboratories (US) is one of the major players in the efficacy testing market. The company’s large market share can be attributed to its robust portfolio that includes traditional as well as innovative technologies and platforms that help streamline the efficacy testing process. The company provides a diverse portfolio of discovery and safety assessment services and offers various products and services to support its clients’ manufacturing activities. Charles River has more than 90 facilities in 20 countries and subsidiaries across the US, Canada, the UK, France, Italy, Spain, the Netherlands, Belgium, Germany, Poland, Ireland, Finland, Luxembourg, Japan, China, India, Korea, Hong Kong, and Australia.

Request Sample Link:

Driver: Rising adoption of quality by design approach

Since the introduction of Quality-by-Design (QbD) concepts, it has been accepted that quality of pharmaceutical products should be designed and built during the manufacturing process. Most of quality problems are related to the way in which a pharmaceutical product was designed. A poor-designed pharmaceutical product will show poor safety and efficacy, no matter how many tests or analyses have been done to verified its quality. Thus, QbD begins with the recognition that quality will not be improved by merely increasing testing of pharmaceutical products. In other words, quality must be built into the product.

Restraint: Adverse effects of chemical disinfectants

Most of the chemical disinfectants currently available in the market have toxic properties. For example, sodium hypochlorite is an effective treatment against blood-borne pathogens but is also highly corrosive and a respiratory irritant, which makes it dangerous for cleaning personnel and building occupants as it causes damage to many surfaces and is toxic when released into the environment. The improper use of these disinfectants can cause environmental hazards and be harmful to patients exposed to them. Disinfectants sold in the US need to be registered with the Environmental Protection Agency (EPA), which classifies these solutions as pesticides; they are regulated under the FIFRA. There is no green certificate currently available for disinfectants in the market.

Due to a growing end-user population demanding greener solutions, the use of disinfectants is becoming limited, with their use being restricted to limited non-critical items and in lower amounts. Manufacturers are now being forced to develop newer and greener alternatives that are less corrosive to the human eyes, such as butyl-free, pH-neutral quaternary, and hydrogen peroxide-based disinfectants. In line with this, in 2021, Clorox Healthcare launched the new Clorox Healthcare Versa-Sure Cleaner Disinfectant Wipes that are alcohol-free.

Recent Developments of Efficacy Testing Industry

  • In 2021, Eurofins Scientific acquired bioskin GmbH (Germany), a dermatology-specific CRO, to strengthen Eurofins’ leadership position in cosmetic product testing.
  • In 2021, Intertek Group plc expanded the company’s Health, Environmental, and Regulatory Consultancy business lines in Spain and Russia.
  • In 2020, 3M launched the TB Quat Disinfectant Ready-to-use Cleaner.
  • In 2020, Ecolab acquired Holchem Group to strengthen its hygiene and cleaning products and services portfolio for the food & beverage, food service, and hospitality industries.

Get 10% Customization:

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on TwitterLinkedIn and Facebook.

Mr. Aashish Mehra
MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: +1-888-600-6441

Email: [email protected]